Agilon Health (NYSE:AGL) Shares Up 9.3% - Should You Buy?

Key Points

• Shares up 9.3% — Agilon traded up to about $8.64 on Wednesday but on very light volume (~31,250 shares, down 88% vs. average) and remains well below its 50‑day and 200‑day moving averages of $14.54 and $18.65.
• Analyst sentiment is mixed — MarketBeat shows a consensus "Hold" (3 Buy / 10 Hold / 2 Sell) with a reported consensus target of $54.38, while individual targets vary widely (Wells Fargo $37.50 overweight vs. Barclays $12.50 underweight and several recent downgrades/price cuts).
• Weak profitability but revenue beat and heavy institutional buying — Agilon missed Q4 EPS ($0.46 loss vs. $0.27 expected) despite revenue beating at $1.57B, has negative net margin and ROE, analysts expect ~‑0.59 EPS this year, and several large funds materially increased their stakes during the quarter.

Agilon Health, Inc. (NYSE:AGL - Get Free Report)'s share price was up 9.3% on Wednesday . The stock traded as high as $8.18 and last traded at $8.6440. Approximately 31,250 shares traded hands during trading, a decline of 88% from the average daily volume of 266,933 shares. The stock had previously closed at $7.91.

Wall Street Analysts Forecast Growth

AGL has been the subject of several recent research reports. BTIG Research reissued a "neutral" rating on shares of Agilon Health in a research report on Friday, December 12th. Citigroup lowered their price objective on Agilon Health from $21.25 to $18.75 and set a "neutral" rating on the stock in a research note on Tuesday, March 3rd. Wells Fargo & Company increased their target price on Agilon Health from $25.00 to $37.50 and gave the stock an "overweight" rating in a report on Friday, February 27th. Barclays cut their target price on Agilon Health from $25.00 to $12.50 and set an "underweight" rating for the company in a research report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Agilon Health in a research note on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $54.38.

Agilon Health Stock Up 16.7%

The firm has a market cap of $3.83 billion, a price-to-earnings ratio of -9.78 and a beta of 0.11. The business's 50-day moving average is $14.54 and its 200-day moving average is $18.65. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.02 and a current ratio of 1.02.

Agilon Health (NYSE:AGL - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.19). The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.46 billion. Agilon Health had a negative net margin of 6.60% and a negative return on equity of 120.82%. On average, equities analysts predict that Agilon Health, Inc. will post -0.59 EPS for the current year.

Institutional Investors Weigh In On Agilon Health

Large investors have recently bought and sold shares of the business. North Peak Capital Management LLC raised its position in Agilon Health by 10.8% in the 4th quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company's stock valued at $26,267,000 after purchasing an additional 3,715,460 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Agilon Health by 196.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company's stock worth $13,812,000 after purchasing an additional 13,283,930 shares during the last quarter. CenterBook Partners LP grew its holdings in shares of Agilon Health by 492.4% during the third quarter. CenterBook Partners LP now owns 11,428,027 shares of the company's stock worth $11,771,000 after purchasing an additional 9,499,012 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Agilon Health by 1,346.6% in the fourth quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company's stock valued at $7,033,000 after buying an additional 9,505,837 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Agilon Health by 30.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,019,002 shares of the company's stock valued at $5,523,000 after buying an additional 1,893,434 shares in the last quarter.

Agilon Health Company Profile

Agilon Health NYSE: AGL is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.